Evaluation of the Efficacy and Treatment-emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-ranging Meta-analysis of 1372 Randomized Patients

Mulham Ahmad Kalantan^1,2*Bader Bashrahil^2*Abdulaziz Aljuaid^2*Hassan Bogari^1,2*Sahal Samarkandy^1,2,3*Abdulhadi Hazzaa Jfri^1,2,3*

• ¹King Saud bin Abdulaziz University for Health Sciences, College of Medicine, Jeddah, Saudi Arabia
• ²King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
• ³Division of Dermatology, Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia

Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the increasing use of janus kinase inhibitors in immune-related conditions, their potential role in AA treatment is gaining attention. Deuruxolitinib has emerged as a potential treatment for moderate to severe AA. This is the first meta-analysis that aims to assess the efficacy of deuruxolitinib in moderate to severe AA. We systematically searched CENTRAL, Medline, and ClinicalTrials.gov for relevant data. Deuruxolitinib vs. placebo was evaluated, and efficacy was measured using Severity of Alopecia Tool (SALT) and Hair Satisfaction Participants Reported Outcome (SPRO), with the primary time point of assessment at week 24. Treatment-emergent adverse events (TEAEs) such as increased creatinine kinase (CPK), acne, and headache were specifically assessed. Effect sizes were presented using mean difference or risk ratio. Statistical heterogeneity was measured by I2, with 95% confidence interval and P-value less than 0.05 considered significant. Risk of bias was assessed using the Revised Cochrane risk of bias tool. Subgroup analysis was conducted for different regimens (8mg, 12mg) and TEAEs of interest. Three RCTs involving 1372 patients were included. Deuruxolitinib demonstrated a significant improvement in SALT score change from baseline (MD=-47.26, 95% CI= [-53.47, -41.05], P<0.00001, I2=76%), with a significant number of patients achieving 75% (RR=93.66, 95% CI= [23.42, 374.65], P<0.00001, I2=0%) and 90% (RR=65.26, 95% CI= [16.28, 261.58], P<0.00001, I2=0%) improvement from baseline. Patients randomized to deuruxolitinib reported a significant improvement in SPRO (MD=-1.52, 95% CI= [-1.76, -1.27], P<0.00001, I2=69%), with many experiencing more than two points of improvement (RR=4.98, 95% CI= [3.79, 6.54], P<0.00001, I2=0%). TEAEs included elevated CPK levels (RR=2.79, 95% CI= [1.5, 4.99], P=0.0006, I2=0%), headaches (RR=1.49, 95% CI= [0.98, 6.54], P=0.06, I2=44%), and acne (significant in the 12mg dose only) (RR=1.80, 95% CI= [0.84, 3.88], P=0.13, I2=64%). In conclusion, deuruxolitinib shows promising efficacy in treating moderate to severe alopecia areata, leading to significant improvements in hair regrowth and patient-reported satisfaction. While certain TEAEs such as increased CPK levels, headaches, and acne, they were generally manageable. Further research and monitoring for long term safety are necessary before widespread adoption of deuruxolitinib for alopecia areata treatment.